guselkumab
Sign in to saveAlso known as Tremfya, CNTO 1959
Guselkumab, sold under the brand name Tremfya, is a human monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.
Key facts
- Drug.type
- mab
- Drug.image
- Tremfya, 100 mg, Guselkumab, autoinjector-6177.jpg
- Drug.alt
- An autoinjector with 100 mg Tremfya, Guselkumab,
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- IL23
- Drug.tradename
- Tremfya
- Drug.MedlinePlus
- a617036
- Drug.DailyMedID
- Guselkumab
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous, intravenous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AC16
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only, Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Manufacturer
- Janssen Biotech
- Image
- Tremfya, 100 mg, Guselkumab, autoinjector-6177.jpg
- Has use
- medication
Show 3 more facts
- World Health Organisation international non-proprietary name
- guselkumab
- defined daily dose
- 1.79
- subject has role
- monoclonal antibody
Sources (3)
via Wikidata · CC0
~3 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Legal status
- Economics
- Names
- Research
- References
Guselkumab, sold under the brand name Tremfya, is a human monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.
== Medical uses == Guselkumab is indicated to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.
Excerpted from Wikipedia’s “guselkumab” article, available under the CC BY-SA 4.0 licence.